The long-term survival of a patient with neuroblastoma suggests the personalized cancer treatment may work for solid tumors, not just blood cancers.

Among 19 neuroblastoma patients treated with CAR T-cell therapy, eight survived more than 5 years after infusion, including five with follow-up of more than 13 years, reported Helen Heslop ...

Helen Heslop and colleagues conducted a phase 1 clinical trial involving 19 children with neuroblastoma, between 2004 and 2009, during which they tested T cells that were engineered to recognize ...

so that she’s grown up and is leading a normal life,” Professor Helen Heslop, co-author of the research from Houston’s Baylor College of Medicine and the director of the Center for Cell and ...